NCT01885338View on ClinicalTrials.gov

N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Schizophrenia
Interventions
DRUG

N-acetylcysteine (NAC)

DRUG

Inactive placebo capsule

Trial Locations (1)

90073

VA West Los Angeles Healthcare Center, Los Angeles

All Listed Sponsors
collaborator

VISN 22 Mental Illness Research, Education, and Clinical Center

FED

collaborator

American Psychiatric Foundation

UNKNOWN

lead

VA Greater Los Angeles Healthcare System

FED

NCT01885338 - N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia | Biotech Hunter | Biotech Hunter